Renal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Renal Cancer Pipeline Insight ' report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Renal Cancer Research. Learn more about our innovative pipeline today! @ Renal Cancer Pipeline Outlook
Key Takeaways from the Renal Cancer Pipeline Report
In February 2025:- H. Lee Moffitt Cancer Center and Research Institute:- The treatment is organized into blocks of 9 weeks, with pembrolizumab treatment planned for weeks 1, 4 and 7. On the second and third blocks, interleukin-2 is added, for 5 doses at a time, one dose every 8 hours, on a weekly schedule on the two weeks after the week 1 and the week 4 pembrolizumab doses.
In February 2025:- Merck Sharp & Dohme LLC:- This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
DelveInsight's Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
The leading Renal Cancer Companies such as Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
Promising Renal Cancer Pipeline Therapies such as Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
Stay informed about the cutting-edge advancements in Renal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Renal Cancer Clinical Trials Assessment
Renal Cancer Emerging Drugs Profile
Atezolizumab : Genentech
Atezolizumab is a monoclonal antibody. It is designed to bind with a protein called PD-L1 expressed on tumor cells and tumor-infiltrating immune cells by blocking its interactions with both PD-1 and B7.1 the drug candidate are programmed cell death-1 ligand-1 inhibitors. Currently it is in Phase III stage of clinical trial evaluation to treat Renal Cancer.
Olaparib: AstraZeneca
Olaparib is a potent and orally active poly (ADP-ribose) polymerase PARP inhibitor thereby blocking the repair of single-strand DNA breaks resulting in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway – homologous recombination being developed for the treatment of renal cell carcinoma. Currently being evaluated in the Phase II studies.
MK-4830 : Merck & Co., Inc
MK-4830 is an investigational first-in-class human monoclonal antibody that inhibits the binding of immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Renal Cancer.
ALLO-316 : Allogene Therapeutics
ALLO-316, an AlloCAR T™ investigational product that targets CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors the drug candidate has received Fast Track Designation (FTD) from U.S FDA based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinoma. The drug is in Phase I stage of clinical trials.
Learn more about Renal Cancer Drugs opportunities in our groundbreaking Renal Cancer Research and development projects @ Renal Cancer Unmet Needs
Renal Cancer Companies
Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others
Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical
Renal Cancer Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Discover the latest advancements in Renal Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Renal Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Renal Cancer Pipeline Report
Coverage- Global
Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Renal Cancer Companies- Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Renal Cancer Pipeline on our website @ Renal Cancer Drugs and Companies
Table of Content
Introduction
Renal Cancer Executive Summary
Renal Cancer: Overview
Renal Cancer Pipeline Therapeutics
Renal Cancer Therapeutic Assessment
Late Stage Products (Phase III)
Comparative Analysis
Atezolizumab: Genentech
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Olaparib: AstraZeneca
Early Stage Products (Phase I)
Allogene Therapeutics: ALLO-316
Inactive Products
Renal Cancer Companies
Renal Cancer Products
Renal Cancer Unmet Needs
Renal Cancer Market Drivers and Barriers
Renal Cancer Future Perspectives and Conclusion
Renal Cancer Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
12 hours ago
- CTV News
Men are more likely than women to die of broken heart syndrome, study finds
Characterized by chest pain, palpitations and shortness of breath, takotsubo cardiomyopathy is thought to be caused by extreme emotional or physical stress. LaylaBird/E+/Getty Images via CNN Newsource A 59-year-old man arrived at the Peking University First Hospital in Beijing for a procedure when he started having severe chest pain and shortness of breath. Four months earlier, he had cancerous tumors removed from his bladder. Around his family, he tried his best to appear strong and avoided discussions of his health. Privately, his severe anxiety over the possibility of a cancer recurrence kept him awake at night. Doctors said the man was experiencing takotsubo cardiomyopathy — also known as broken heart syndrome, as documented in a 2021 case study. The rare stress-induced heart condition has been observed primarily in women, but a study published in the Journal of the American Heart Association in May found that the illness may be more deadly for the men who get it. Thought to be caused by extreme emotional or physical events — such as learning about the death of a loved one, winning the lottery or lifting a heavy sofa — takotsubo cardiomyopathy, or TC, occurs when the heart muscle is flooded with stress hormones, causing part of it to 'freeze' in place. As the heart struggles to properly pump blood, symptoms resemble those of a heart attack, including chest pain, heart palpitations and irregular heartbeat. The new study analyzed data from nearly 200,000 patients hospitalized for TC in the United States between 2016 and 2020. While women accounted for 83% of the cases, men were more than twice as likely to die from the condition — with a mortality rate of 11.2%. 'The differences between men and women are a very striking finding,' said study coauthor Dr. Mohammad Reza Movahed, a clinical professor of medicine at the University of Arizona in Tucson. 'It raises a new, interesting question that should really be studied.' Broken heart syndrome in men vs. women Similar to differences between men's and women's cardiovascular health more generally, the discrepancies in TC death rates are not well understood, Movahed said, especially because they counter trends in other heart diseases. It's widely theorized, however, that differences in hormone levels play a role. Stressful situations trigger the adrenal glands to release our fight-or-flight hormones, called catecholamines. They are meant to increase our blood pressure and raise our heart rate, but extreme levels can temporarily 'stun' cells in the heart's tissue, leading to TC, Movahed explained. Men are thought to produce more catecholamines during stressful situations compared with women, possibly leading men to present with more severe cases of TC, he suggested. Estrogen, a sex hormone produced at higher levels in women, may also have a protective effect on the cardiovascular system, making it easier to manage an extreme influx of catecholamines and reducing the risk of severe complications from TC, said Dr. Louis Vincent, a noninvasive-cardiology research fellow at the University of Miami, who coauthored a similar, multiyear study investigating discrepancies in men and women who had TC. Vincent was not involved in the new study. Beyond biological differences, social factors may play a role as well. 'Most (physicians) know about takotsubo, but they may think of it as a disease just affecting women, so the diagnosis might be overlooked in men,' said Dr. Deepak Bhatt, a cardiologist and the director of Mount Sinai Fuster Heart Hospital who was not involved in the study. 'With misdiagnosis, care is delayed, and that can sometimes lead to worse outcomes.' Men may also seek care at a later stage of illness, believing that their symptoms are manageable or may pass, said Dr. Alejandro Lemor, an assistant professor of interventional cardiology at the University of Mississippi Medical Center who was also not involved in the study. Deadly complications from TC include blood clots, stroke, cardiac arrest and heart failure, Lemor said. If the condition is caught early, medications can reduce the risk of having these complications, restore proper heart function and allow for full recovery within weeks, he added. Higher mortality rates in men need further study Movahed's team was able to factor for important variables like age, race, income, chronic lung disease, hypertension and diabetes in the findings. However, there was no patient data on other comorbid diseases, such as a history of stroke or the presence of a Covid-19 infection, Vincent said. Additionally, the new study included in-patient diagnostic data only for those hospitalized with TC, so those who received outpatient care or died later from complications outside the hospital were likely not counted in the analysis, Movahed noted. To establish a firmer explanation for the differences in mortality rates between men and women and further test treatment methods, a more detailed dataset would be needed, Vincent said. 'People should be aware in studies like this, we're presenting findings that are based on diagnostic codes, and we're not looking at patient procedures or lab results,' Vincent said. 'But it's powerful in the sense that it lets us look at large populations and look at trends. And I think that this trend of a higher mortality in men is worth taking a deeper look into.' Don't try to 'tough it out' Sudden, severe chest pain or shortness of breath should always be treated as a medical emergency, warned Bhatt, who is also a professor of cardiovascular medicine at the Icahn School of Medicine at Mount Sinai in New York City. 'It's not a time to tough it out at home or get on the internet to figure it out. … Don't try to track down your primary care provider. Call emergency services,' Bhatt said. 'Time matters. By winning those few hours, you could save yourself irreparable damage to your heart.' Symptoms following physical stressors — a common cause of TC in men — should not be ignored, Movahed said, especially preceding medical events such as asthma attacks, seizures or complications from drug use. And while TC is caused by sudden stress, Bhatt said that managing chronic stress with daily meditation or exercise can lead to better cardiovascular health overall while giving you routines to fall back on in unexpected situations.
CTV News
a day ago
- CTV News
Ticats GM says he has been diagnosed with ‘a serious form of cancer'
Hamilton Tiger-Cats general manager Ted Goveia says he has been diagnosed with "a serious form of cancer that's spread." In a story posted on the club's website Friday, Goveia, 55, said the diagnosis was made in April. Although there was no specific mention as to the form of the disease, two league sources said Goveia is battling esophageal cancer. "I wanted to keep my health condition in house until we had a chance to build our team and pick our final roster," he said. "I am grateful that we were able to focus on fielding the best team possible for 2025 and not have my health become a distraction. "I let the players know that I'm not going to be here (at team facilities) every minute of the day, and I'm going to be in treatment and need to focus on my health. I'm still the general manager, but I'll not always be in the building. But in today's day and age, everything's downloaded to my laptop and there's always the phone." Goveia, of Burlington, Ont., was named Hamilton's GM on Dec. 5, 2024, following 11 years with the Winnipeg Blue Bombers. The appointment was a homecoming for Goveia, who played high school football at Assumption Secondary School and later coached there as well as other local organizations. Goveia's early days as Ticats' GM were long and busy as he put together a staff while looking to improve a roster that last year missed the CFL playoffs. All the while getting to know the people in his new workplace. But in March, Goveia told The Canadian Press he never had to look far to gain a sense of perspective or appreciation that he'd landed his dream job. 'The other morning I went into the office at 6:30 a.m.,' Goveia said. 'Got up, grabbed my coffee and drove over the (Burlington Skyway) bridge and I'm looking out and the sun was coming up. 'I just sat there smiling as I drove thinking, 'Man, I'm 17 minutes from home.' I do love southern Ontario and appreciate the opportunity to work back at home, for sure.' Hamilton (7-11) missed the 2024 CFL playoffs and last won the Grey Cup in 1999. "Our CFL family and the entire CFL community sends its best wishes to Ted Goveia after learning of his cancer diagnosis," CFL commissioner Stewart Johnston said in a statement. "Fans from coast to coast to coast send their strength to you and your family. "Your journey through the game has been an incredible inspiration to us all, and we're here now to support you every step of the way throughout this courageous fight." Goveia began his tenure in Winnipeg as the club's assistant GM/player-personnel director before being promoted to senior assistant GM in 2019 following the franchise's 33-12 Grey Cup win over Hamilton. Goveia said being away from the team while undergoing treatment will only serve to motivate him in his fight. "I enjoy being around our players and I will miss the daily interaction — it motivates me to kick this and get back with the team," he said. "I feel like we're in good shape, but I did have to meet with everybody in the building because I thought they had the right to know. "As difficult a conversation as it is to have, I owe that to the players and to the people who are working here.' And Goveia said the Ticats are in very good hands at this time. "I'm not at all concerned that we're going to be able to function well throughout this,' he said. "I don't have one worry about that. "I feel like we're in good shape, and I think we've got a bunch of rising stars (in football operations)." Goveia began his CFL career with the Toronto Argonauts in 2010, serving as running backs coach and director of Canadian scouting before being promoted to player-personnel director. Over his four seasons with the club (2010-13), it reached the playoffs three times and captured the 100th Grey Cup in 2012 under then-head coach Scott Milanovich, who's entering his second season as Hamilton's head coach/offensive co-ordinator. Goveia would later be on two Grey Cup-winning squads in Winnipeg (2019, 2021). Before making the move to the CFL, Goveia spent 15 years coaching Canadian university football, including stops at his alma mater, Mount Allison, McMaster, and the University of British Columbia. This report by The Canadian Press was first published June 6, 2025. Dan Ralph, The Canadian Press
CBC
2 days ago
- CBC
Marc Garneau died after 'short but very difficult battle' with cancer, former staffer says
Social Sharing Marc Garneau died this week after being diagnosed with two types of cancer earlier this year, his former staffer says. The first Canadian to travel to space and former cabinet minister died on Wednesday. He was 76. Marc Roy, Garneau's former chief of staff, told CBC's Power & Politics that the former minister had been diagnosed with lymphoma and leukemia earlier this year. "He fought a short but very difficult battle with two very rare types of cancer," Roy told host David Cochrane. "Although his diagnosis was only a couple of months ago, he was well until four or five weeks ago. So it went very, very quickly … it's a very, very tough loss." Roy said Garneau only shared his diagnosis with a small circle that agreed to respect his wish for privacy. "[It was] something he wanted to keep with his family so he could concentrate on his time with his family and not distract his family by the attention it could have gotten," Roy said. Marc Garneau's 'extraordinary ride' through space, life and politics 8 months ago Duration 9:16 Chief political correspondent Rosemary Barton speaks with former Liberal minister of foreign affairs and Canada's first astronaut Marc Garneau, about his life on this planet and outside of it: being the first Canadian astronaut, his political career and his relationship with the prime minister. Beyond his legacy as an astronaut, Garneau held a number of federal cabinet positions since 2015, including in transport and foreign affairs. Roy said Garneau was "tremendous" to work for as he reflected on his time in politics. "It's a huge loss to government. I think that his years in Ottawa are filled with many contributions to improving safety and expanding policy. I think he will be remembered for that for decades to come," Roy said. MPs pay homage to former colleague The House of Commons held another moment of silence for Garneau on Thursday and MPs took time to pay tribute to their former colleague. "He reminded us that Canadians can dream big, that we could aim for the stars quite literally," Government House leader Steve MacKinnon said. "He became a powerful symbol of the achievement and the accomplishment of this great country of ours." Like MacKinnon, other MPs reflected on how Garneau inspired Canadians. "Mr. Garneau, the future will always be inspired by your life, which was so inspiring for all Canadians," Conservative MP Gérard Deltell said in French. Bloc Québécois MP Rhéal Fortin said Garneau paved the way for other Canadians to journey to space, including Chris Hadfield and Julie Payette. "He showed us the way to the stars," Fortin said in French. Fighting back tears, Green Party Leader Elizabeth May said it was hard to say goodbye to "someone who was unfailingly kind [and] unfailingly respectful." "We've lost a very great human being, and to his entire family: my deepest condolences and sympathy — and know that in that space where he looks down at planet Earth now, I think it's a place called heaven."
